Key result
Sacubitril/valsartan has established efficacy for treating chronic heart failure with reduced ejection fraction, prompting evaluation of its future clinical role based on recent guidelines.
Answers are grounded in this paper and cite their sources.
This review discusses the future place in therapy for sacubitril/valsartan in chronic heart failure with reduced ejection fraction following its launch and the PARADIGM-HF trial.
Sacubitril/valsartan (Entresto), a combined neprilysin inhibitor/angiotensin II‐receptor antagonist for the treatment of chronic heart failure with reduced ejection fraction, was launched in the UK in January. The phase 3 clinical trial PARADIGM‐HF established its efficacy in chronic heart failure but what is its future place in therapy, according to the latest guidelines and research?
No takes yet. Share an insight, caveat, or question.
Steve Chaplin (2016) studied this question. Sacubitril/valsartan has established efficacy for treating chronic heart failure with reduced ejection fraction, prompting evaluation of its future clinical role based on recent guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: